MétaCan
Menu
Back to cohort
Record W7109225702 · doi:10.71889/5fylantbak.30801974

A commercialized dietary supplement alleviates joint pain in community adults: a double-blind, placebo-controlled community trial

2013· article· W7109225702 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

aboutThe title or abstract carries a Canadian signal from the geographic lexicon.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

VenueAppalachian State University · 2013
Typearticle
Language
FieldMedicine
TopicPharmacological Effects of Medicinal Plants
Canadian institutionsnot available
Fundersnot available
KeywordsPlaceboJoint painOsteoarthritisQuality of life (healthcare)Randomized controlled trialViscosupplementationWOMACVisual analogue scale

Abstract

fetched live from OpenAlex

Background-The purpose of this study was to assess the effect of 8-weeks ingestion of a commercialized joint pain dietarysupplement (InstaflexTM Joint Support, Direct Digital, Charlotte, NC) compared to placebo on joint pain, stiffness, and function in adults with self-reported joint pain. InstaflexTM is a joint pain supplement containing glucosamine sulfate, methylsufonlylmethane (MSM), white willow bark extract (15% salicin), ginger root concentrate, boswella serrata extract(65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid.Methods- Subjects included 100 men and women, ages 50-75 years, with a history (>3 months) of joint pain, and were randomized to Instaflex™ or placebo (3 colored gel capsules per day for 8 weeks, double-blind administration). Subjectsagreed to avoid the use of non-steroidal anti-inflammatory drugs (NSAID) and all other medications and supplementsmtargeted for joint pain. Primary outcome measures were obtained pre- and post-study and included joint pain severity,stiffness, and function (Western Ontario and McMaster Universities [WOMAC]), and secondary outcome measures included health-related quality of life (Short Form 36 or SF-36), systemic inflammation (serum C-reactive protein and 9plasma cytokines), and physical function (6-minute walk test). Joint pain symptom severity was assessed bi-weekly using a12-point Likert visual scale (12-VS).Results- Joint pain severity was significantly reduced in Instaflex™ compared to placebo (8-week WOMAC, ?37% versus?16%, respectively, interaction effect P=0.025), with group differences using the 12-VS emerging by week 4 of the study(interaction effect, P=0.0125). Improvements in ability to perform daily activities and stiffness scores in Instaflex™ comparedto placebo were most evident for the 74% of subjects reporting knee pain (8-week WOMAC function score, ?39% versus?14%, respectively, interaction effect P=0.027; stiffness score, ?30% versus ?12%, respectively, interaction effect P=0.081). Patterns of change in SF-36, systemic inflammation biomarkers, and the 6-minute walk test did not differ significantly between groups during the 8-week studyConclusions-Results from this randomized, double blind, placebo-controlled community trial support the use of the Instaflex™ dietary supplement in alleviating joint pain severity in middle-aged and older adults, with mitigation of difficultyperforming daily activities most apparent in subjects with knee pain.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.017
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Science and technology studies, Research integrity, Insufficient payload (model declined to judge)
Consensus categoriesMeta-epidemiology (narrow)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.105
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0170.002
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.001
Bibliometrics0.0010.001
Science and technology studies0.0020.001
Scholarly communication0.0000.001
Open science0.0020.002
Research integrity0.0010.009
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.299
Teacher spread0.243 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it